Free Trial
NASDAQ:ALDX

Aldeyra Therapeutics Q4 2024 Earnings Report

Aldeyra Therapeutics logo
$4.95 +0.02 (+0.41%)
Closing price 09/22/2025 04:00 PM Eastern
Extended Trading
$4.92 -0.03 (-0.51%)
As of 07:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aldeyra Therapeutics EPS Results

Actual EPS
-$0.27
Consensus EPS
$0.03
Beat/Miss
Missed by -$0.30
One Year Ago EPS
N/A

Aldeyra Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Aldeyra Therapeutics Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Friday, February 28, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Aldeyra Therapeutics' Q3 2025 earnings is scheduled for Thursday, November 6, 2025, with a conference call scheduled at 3:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Aldeyra Therapeutics Earnings Headlines

Make this AI Trade Before EOM
President Trump is set to sign a game-changing new law… That I believe will trigger a boom in a handful of artificial intelligence coins… Giving you a chance to turn a small stake into a six-figure payout.tc pixel
See More Aldeyra Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aldeyra Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aldeyra Therapeutics and other key companies, straight to your email.

About Aldeyra Therapeutics

Aldeyra Therapeutics (NASDAQ:ALDX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis. Aldeyra is also developing ADX-2191, an intravitreal formulation targeting proliferative vitreoretinopathy, a serious complication of retinal detachment surgery. In addition to its ophthalmology pipeline, Aldeyra has earlier-stage programs exploring systemic indications where reactive aldehyde species contribute to inflammation and tissue damage.

Founded in 2009 and headquartered in Lexington, Massachusetts, Aldeyra is led by a management team with extensive experience in ophthalmology and biopharmaceutical development. Under the leadership of Chief Executive Officer Fredric A. Hargreaves, the company collaborates with clinical research centers across North America and Europe to advance its pipeline through late-stage clinical trials. Aldeyra’s strategy emphasizes rigorous clinical validation, strategic partnerships and readiness for commercial launch upon regulatory approval.

View Aldeyra Therapeutics Profile

More Earnings Resources from MarketBeat